[
  {
    "ts": null,
    "headline": "Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts",
    "summary": "The latest trading day saw Boston Scientific (BSX) settling at $95.85, representing a -1.82% change from its previous close.",
    "url": "https://finnhub.io/api/news?id=e9beeea6ebf8dd9d9cf61229536200ea50544b1baf47b3f81175c5aa8c63e12d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759356003,
      "headline": "Boston Scientific (BSX) Stock Dips While Market Gains: Key Facts",
      "id": 136952334,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The latest trading day saw Boston Scientific (BSX) settling at $95.85, representing a -1.82% change from its previous close.",
      "url": "https://finnhub.io/api/news?id=e9beeea6ebf8dd9d9cf61229536200ea50544b1baf47b3f81175c5aa8c63e12d"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Corp. stock underperforms Wednesday when compared to competitors",
    "summary": "Boston Scientific Corp. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=7219f3a8427567d885852de9131c713d9feab2cdf86392afda00710a801e2d2b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759336500,
      "headline": "Boston Scientific Corp. stock underperforms Wednesday when compared to competitors",
      "id": 137016960,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific Corp. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=7219f3a8427567d885852de9131c713d9feab2cdf86392afda00710a801e2d2b"
    }
  },
  {
    "ts": null,
    "headline": "Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum",
    "summary": "HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.",
    "url": "https://finnhub.io/api/news?id=aded1309859837a9be38074d140583cef3bd367dcf064e673234432713cbe87d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759324200,
      "headline": "Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum",
      "id": 136947441,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.",
      "url": "https://finnhub.io/api/news?id=aded1309859837a9be38074d140583cef3bd367dcf064e673234432713cbe87d"
    }
  },
  {
    "ts": null,
    "headline": "Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million",
    "summary": "- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the closing of the sale of its BioEnvelope business, including the EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation (NYSE: B",
    "url": "https://finnhub.io/api/news?id=3f2542f0fade9aa2e80e44bd9e6ed08001c9e06044948c62d4d97baf94ee854d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759322460,
      "headline": "Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million",
      "id": 136946541,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "- Strengthened balance sheet to fully fund development and launch of NXT-41 platform - - Biologics for breast reconstruction represents $1.5 billion U.S. total addressable market - GAITHERSBURG, Md., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced the closing of the sale of its BioEnvelope business, including the EluPro™ and CanGaroo® bioenvelopes, to Boston Scientific Corporation (NYSE: B",
      "url": "https://finnhub.io/api/news?id=3f2542f0fade9aa2e80e44bd9e6ed08001c9e06044948c62d4d97baf94ee854d"
    }
  },
  {
    "ts": null,
    "headline": "BTIG Maintains Boston Scientific (BSX) Buy Recommendation",
    "summary": "BTIG Maintains Boston Scientific (BSX) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=35cdbf633d6b87d098fb4f72b5eaaec7ffc2685ea5b082b8199442cd1142d6d3",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759320222,
      "headline": "BTIG Maintains Boston Scientific (BSX) Buy Recommendation",
      "id": 136945377,
      "image": "",
      "related": "BSX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=35cdbf633d6b87d098fb4f72b5eaaec7ffc2685ea5b082b8199442cd1142d6d3"
    }
  },
  {
    "ts": null,
    "headline": "Needham Reiterates Boston Scientific (BSX) Buy Recommendation",
    "summary": "Needham Reiterates Boston Scientific (BSX) Buy Recommendation",
    "url": "https://finnhub.io/api/news?id=5e146289889ad982599c15deb1ae8d69bb31236d9c2532366e063a9596eb3a8b",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759320209,
      "headline": "Needham Reiterates Boston Scientific (BSX) Buy Recommendation",
      "id": 136945381,
      "image": "",
      "related": "BSX",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5e146289889ad982599c15deb1ae8d69bb31236d9c2532366e063a9596eb3a8b"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific unveils plans for new Watchman device",
    "summary": "The company hopes to launch its next-generation Watchman system in the second half of 2027 or early 2028.",
    "url": "https://finnhub.io/api/news?id=dd230356318bebec2f271887289bd21ec3dddc8d8522b00bc1ab4c38e4f3f736",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759316137,
      "headline": "Boston Scientific unveils plans for new Watchman device",
      "id": 136947443,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "The company hopes to launch its next-generation Watchman system in the second half of 2027 or early 2028.",
      "url": "https://finnhub.io/api/news?id=dd230356318bebec2f271887289bd21ec3dddc8d8522b00bc1ab4c38e4f3f736"
    }
  }
]